{"nctId":"NCT02434770","briefTitle":"Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine","startDateStruct":{"date":"2015-08"},"conditions":["Poliomyelitis"],"count":750,"armGroups":[{"label":"BBIBP bOPV Lot 1","type":"EXPERIMENTAL","interventionNames":["Biological: BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1"]},{"label":"BBIBP bOPV Lot 2","type":"EXPERIMENTAL","interventionNames":["Biological: BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2"]},{"label":"BioFarma bOPV","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: BioFarma Bivalent Oral Poliomyelitis Vaccine"]}],"interventions":[{"name":"BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1","otherNames":["Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral"]},{"name":"BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2","otherNames":["Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral"]},{"name":"BioFarma Bivalent Oral Poliomyelitis Vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy, full-term infants, as established by medical history and clinical examination before entering into the study.\n* Parents willing to provide written informed consent.\n* Age: infants less than 2 weeks of age at the time of enrollment (from the 1st through the 14th day of life, inclusive)\n\nExclusion Criteria:\n\n* Birth weight (as documented at first medical contact) less than 2.5 kg\n* Presence of diarrhea or vomiting in the previous 24 hours or on the day of enrollment (temporary exclusion)\n* Presence of fever (\\> 37.5°C) on the day of enrollment (temporary exclusion)\n* Acute disease at the time of enrollment (temporary exclusion)\n* Significant malnutrition as per Investigator's judgment\n* Concurrent participation in another clinical study at any time during the study period in which the infant will be exposed to an investigational or a non-investigational product\n* Presence of any significant systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination which would compromise the child's health or is likely to result in non-conformance to the protocol\n* Known or suspected impairment of immunological function (including human immunodeficiency virus \\[HIV\\] exposure) based on medical history and physical examination\n* Previous receipt of polio virus vaccine\n* Household contact with a known immunosuppressed individual\n* Unwillingness or inability of parents for active follow-up by the study staff\n* History of any neurological disorders or seizures\n* Any medical condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence or a participant's ability to give informed consent\n* Maternal HIV infection","healthyVolunteers":true,"sex":"ALL","minimumAge":"1 Day","maximumAge":"14 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Experiencing Any Systemic Reactogenicity, by Maximum Severity","description":"Solicited systemic reactogenicity events evaluated during the week after each vaccination included fever, vomiting, diarrhea, decreased appetite/ poor feeding, irritability, and decreased activity. Reactions were recorded by participant's parents via memory aid. Each event was graded as:\n\nMild (Grade 1): No or minimal interference with usual activities; no medical intervention/therapy required, Moderate (Grade 2): Greater than minimal interference with usual activities; no or minimal medical intervention/therapy required, Severe (Grade 3): Marked limitation in ability to perform usual activities; medical intervention/therapy required, or Potentially life-threatening (Grade 4): Inability to perform basic functions OR Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.\n\nThe overall number of participants who experienced any systemic reaction is reported. Grades are based on maximum severity per participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"179","spread":null},{"groupId":"OG002","value":"175","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"139","spread":null},{"groupId":"OG002","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events","description":"Adverse events were graded as mild (Grade 1 = No or minimal interference with usual activities; no medical intervention/therapy required), moderate (Grade 2 = Greater than minimal interference with usual activities; no or minimal medical intervention/therapy required), severe (Grade 3 = Marked limitation in ability to perform usual activities; medical intervention/therapy required), or potentially life-threatening (Grade 4 = Inability to perform basic functions OR Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death).\n\nThe overall number of participants who experienced any adverse event is reported. Grades are based on maximum severity per participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"151","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-polio Neutralizing Antibody Geometric Mean Titers (GMT): Serotype 1","description":"The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.\n\nAnti-polio antibody titer four weeks after the fourth vaccination was adjusted for the decrease in maternal antibodies based on a half-life of 28 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.9","spread":null},{"groupId":"OG001","value":"41.5","spread":null},{"groupId":"OG002","value":"41.2","spread":null},{"groupId":"OG003","value":"47.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55192","spread":null},{"groupId":"OG001","value":"65790","spread":null},{"groupId":"OG002","value":"60151","spread":null},{"groupId":"OG003","value":"55634","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-polio Neutralizing Antibody Geometric Mean Titers: Serotype 3","description":"The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.\n\nAnti-polio antibody titer four weeks after the fourth vaccination was adjusted for the decrease in maternal antibodies based on a half-life of 28 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"15.6","spread":null},{"groupId":"OG002","value":"13.9","spread":null},{"groupId":"OG003","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11374","spread":null},{"groupId":"OG001","value":"12390","spread":null},{"groupId":"OG002","value":"11861","spread":null},{"groupId":"OG003","value":"8063","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Infants With Serotype-specific Anti-polio Neutralizing Antibody Seroconversion 4 Weeks After Last Dose","description":"The assays for determination of anti-poliovirus neutralizing antibodies at the National Institutes for Food and Drug Control (NIFDC) were validated.\n\nSeroconversion was defined as a titer ≥ 1:8 if seronegative at screening, otherwise a ≥ 4-fold increase in adjusted titers (i.e., adjusted for the decay in maternal antibodies, based on a half life of 28 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":null},{"groupId":"OG001","value":"215","spread":null},{"groupId":"OG002","value":"438","spread":null},{"groupId":"OG003","value":"219","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":null},{"groupId":"OG001","value":"214","spread":null},{"groupId":"OG002","value":"437","spread":null},{"groupId":"OG003","value":"217","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-hepatitis B Surface Antigen (HBsAg) Geometric Mean Titers","description":"Anti-HBsAg titers were measured to assess the impact of concomitant administration of BBIBP liquid bOPV on immune responses to other Expanded Programme on Immunization (EPI) vaccines in comparison to that of the WHO pre-qualified bOPV, 4 weeks after the fourth vaccination.\n\nThe enzyme-linked immunosorbent assay (ELISA) assays for serum antibodies to HBsAg were performed at the Children's Hospital Medical Center (CCHMC). The HBsAb assay was a qualified assay using a kit from BioRad.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320","spread":null},{"groupId":"OG001","value":"322","spread":null},{"groupId":"OG002","value":"321","spread":null},{"groupId":"OG003","value":"267","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Infants With Anti-hepatitis B Surface Antigen (HBsAg) Seroprotection","description":"Seroprotection was defined as a HBsAg titer ≥ 1:10 The ELISA assays for serum antibodies to HBsAg were performed at the Children's Hospital Medical Center (CCHMC). The HBsAb assay was a qualified assay using a kit from BioRad.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"194","spread":null},{"groupId":"OG002","value":"386","spread":null},{"groupId":"OG003","value":"196","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Rotavirus Immunoglobulin A (IgA) Geometric Mean Titers","description":"Anti-rotavirus immunoglobulin A titers were measured to assess the impact of concomitant administration of BBIBP liquid bOPV on immune responses to other Expanded Programme on Immunization (EPI) vaccines in comparison to that of the WHO pre-qualified bOPV, 4 weeks after the fourth vaccination.\n\nThe ELISA assay for antibodies to rotavirus was performed at the Children's Hospital Medical Center (CCHMC) using a validated in-house assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"35.8","spread":null},{"groupId":"OG002","value":"28.3","spread":null},{"groupId":"OG003","value":"28.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":249},"commonTop":["Upper respiratory tract infection","Abdominal pain","Miliaria","Conjunctivitis","Diarrhoea"]}}}